Phase I/II Study of Pembrolizumab + Favezelimab, an Anti–LAG-3 mAb, in R/R Classical Hodgkin Lymphoma

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
Preliminary data suggest that combined treatment with anti–PD-1 and anti–LAG-3 agents provides antitumor activity with a high response rate and durable responses in patients with R/R classical Hodgkin lymphoma naive to anti–PD-1 treatment.
Format: Microsoft PowerPoint (.ppt)
File Size: 122 KB
Released: June 15, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings